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Abstract
Background: Human papillomavirus (HPV) infection is a major risk factor for the development of nearly all cases of
cervical cancer worldwide. The presence of HPV DNA in cases of esophageal squamous-cell carcinoma (ESCC) has
been reported repeatedly from Shantou, China, and other regions with a high incidence of esophageal carcinoma
(EC). However, unlike in cervical squamous-cell carcinoma (CSCC), in ESCC, the characteristics of HPV are unclear.
Thus, the role of high-risk HPV types in the carcinogenesis of ESCC remains uncertain.
Methods: Seventy cases of ESCC with 60 controls and 39 cases of CSCC with 54 controls collected from patients
in Shantou region in China were compared for the distributions of HPV-16, -18 and -58; viral load; and viral
integration using real-time PCR assay and HPV-16 expression using immunostaining.
Results: The detection rates and viral loads of HR-HPV infection were significantly lower in ESCC than in CSCC
(50.0% vs. 79.48%, P = 0.005; 2.55 ± 3.19 vs. 361.29 ± 441.75, P = 0.002, respectively). The combined integration
level of HPV-16, -18 and -58 was slightly lower in ESCC than in CSCC (P = 0.022). HPV-16 expression was detected
in 59.26% of ESCC tissue and significantly associated with tumour grade (P = 0.027).
Conclusions: High levels of HR-HPV expression and integration may be an indicator of the risk of ESCC, at least for
patients in the Shantou region of China. However, a relatively low HPV copy number and infection rate in ESCC is
unlikely to play an essential a role in the carcinogenesis of ESCC as in cervical cancer. Factors other than HR-HPV
infection may contribute to the carcinogenesis of ESCC.
Background
Esophageal squamous cell carcinoma (ESCC) occurs
worldwide and has a variable geographic distribution
[1]. The Shantou coastal area of eastern Guangdong
province, in southern China, has a high incidence of
esophageal carcinoma (EC) [2]. Tobacco smoking, alco-
hol drinking, dietary deficiency, and some local factors,
including drinking hot tea and consumption of fermen-
ted fish sauce, may be involved in the development of
EC in this region [3,4]. However, the etiology of EC is
still largely unknown.
The association of HPV infection and EC has been
reported in the last 30 years, especially in geographic
areas with a high incidence of EC. However, unlike cer-
vical carcinoma, with its almost conclusive association
with HPV, the causal role of HPV infection in EC
remains controversial. This lack of association is due in
part to the wide variation in reported infection rates
among different studies (from 0% to more than 60%),
and few studies have related HPV status to genetic
changes [5]. These variations may reflect a difference in
HPV infection rates in EC cases collected from different
geographic regions. However, differences in sensitivity
and specificity of the detection methods may also be
contributors. Previously, we found a high prevalence of
HPV infection in esophageal cancerous (65.5%) and
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esophagus (60.0%) tissues in the Shantou region by a
regular PCR method [6]. In addition, our in vitro experi-
ments indicated that expression of the HPV-18 E6/7
gene was sufficient to induce cellular immortality,
including cellular proliferation, telomerase activity and
chromosome instability [7].
More than 40 genotypes of HPV that infect the ano-
genital area are associated with a large spectrum of dis-
eases from benign proliferative to invasive cancers. In
China, a meta-analysis revealed that high percentages of
cervical cancer cases mainly attributed to the 3 most
frequent high-risk types of HPV (HR-HPV): HPV-16 is
involved in more than half of the cervical cancer cases,
and HPV-18 and -58, approximately 11.0% and 7.2%,
respectively [8]. Recent studies have suggested a high
correlation between HR-HPV viral load (notably HPV-
16) and high-grade squamous-cell intraepithelial lesions
[9,10]. In addition, the disruption of the HPV E2 gene
during viral integration, which results in a loss of its
function as a regulator of viral oncogene expression and
subsequent upregulation of E6/E7 gene transcription,
may initiate cell transformation and immortality by
deregulating the tumor suppressor gene products p53
and retinoblastoma protein [11]. Thus, both HR-HPV
DNA load and its integration may be 2 candidate mar-
kers that could help identify high risk of progression of
cervical intraepithelial neoplasms and forecast cervical
lesions in patients with chronic infection. In addition,
despite multiple investigations based on various study
designs and methodologies, the clinical utility of HR-
HPV DNA load remains unclear [12].
Only one study detailing the characteristics of HR-
HPV DNA load in ESCC from the Shantou region has
been reported; median copy numbers (11.7-14.6 copies/
genome equivalents) were relatively higher than that in
other regions in China, with frequent integration of
HPV-16 DNA in the host genome. In this study, only
four HPV-16-positive ESCC cases were detected [13].
Thus, a discrepancy in findings is inevitable considering
the relatively small number of samples. We aimed to
characterize the prevalence, viral load and physical sta-
tus of the 3 most common HPV types, HR-HPV-16, -18
and - 58, in ESCC and CSCC and their corresponding
control tissues. We used a real-time PCR-based method
for measurement of HPV-16, -18 and -58 viral load and
physical status in clinical samples. This method is accu-
rate and sensitive for detecting as few as 50 copies of
integrated HPV DNA in clinical samples [14]. We
hoped to increase our knowledge of HR-HPV-induced
esophageal and cervical carcinogenesis. Further, HPV-16
expression was detected by immunohistochemistry
(IHC) to evaluate its role in ESCC tissue.
Methods
Subjects and Study Design
The study was carried out in compliance with the
Declaration of Helsinki and was approved by the Ethics
Committee of Shantou University Medical College. All
subjects gave their written informed consent to partici-
pate in the study (Department of Medical Oncology,
Affiliated Cancer Hospital of Shantou University Medi-
cal College, China).
Fresh ESCC tissue was from 70 patients with ESCC
(49 males; mean age 57.32 ± 8.44 years; 21 females;
mean age 59.95 ± 8.77 years) and 60 subjects with nor-
mal esophageal tissue (38 males; mean age 31.73 ± 8.62
years; 22 females; mean age 45.91 ± 5.72 years) from the
Department of Thoracic Surgery in the Affiliated Tumor
Hospital of Shantou University Medical College from
2002 to 2006. Control samples were from post-mortem
paraffin-embedded esophageal tissue without lesions of
subjects who died due to trauma (in the hospital or
daily life [mainly traffic accidents and regular daily
labor]) or cardiocerebrovascular disease. Fresh CSCC
tissue was from 39 patients with CSCC (mean age 43.10
± 8.16 years) and 54 patients with normal cervical tissue
(mean age 44.14 ± 8.27 years) from the Department of
Gynecological Tumors of the Affiliated Tumor Hospital
of Shantou University Medical College from 2006 to
2008. We collected 54 paraffin-embedded samples from
each of 54 ESCC patients (mean age 52.52 ± 9.89 years)
from the Affiliated Tumor Hospital of Shantou Univer-
sity Medical College from 1991 to 1995. All subjects
had lived or were living in the Shantou region.
Hematoxylin and eosin-stained tissue sections from
ESCC, CSCC, and corresponding control tissue were
reviewed by Professor Shen Zhongying from the Insti-
tute of Oncology Pathology to confirm the original
findings and define representative tumor regions.
Tumor stage and grade were defined according to the
World Health Organization histological classification
criteria [15].
HPV plasmid construction
pMD™ 18-T Simple Vector (Takara Biotechnology
[DALIAN] Co., Japan) plasmids containing E2 and E6/7
genes for HPV-16, -18, -58 were prepared by cloning
their corresponding PCR products from clinical samples.
The inserted fragments were confirmed by sequencing
and PCR amplification. The plasmids were used as posi-
tive controls. PCR primer sequences are in Table 1.
Real-time PCR for HR-HPV E2 and E6/7
Fresh samples from the ESCC and CSCC cases and their
controls were used for HPV detection and genotyping
with high-sensitive real-time PCR. The plasmid stock
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quantification gradient of 10
10,1 0
8,1 0
6,1 0
4,1 0
2 and 1
copy. Real-time PCR reactions involved use of an ABI
Prism® 7300 system. The 25-μl reaction mixture
included SYBR® Premix Ex Taq™ (Takara Biotechnology
[DALIAN] Co.); forward and reverse primers at 10
pmol/ml for HPV-16, -18 and -58 E2 or E6/7 genes; and
2 μl DNA sample. PCR reactions were as follows: 50°C
for 2 min, denaturing at 95°C for 5 min, then 40 cycles
of 95°C for 15 sec and 60°C for 31 sec. Positive (corre-
sponding plasmid) and negative (no DNA template)
controls were introduced systematically in each reaction
plate. Each sample was tested in duplicate. All experi-
ments were repeated and confirmed separately by use of
the Mx3000P™Real-Time PCR System (Agilent, Santa
Clara, CA, USA).
Validation of real-time PCR for HPV load and physical
status
The detection limit of the real-time PCR method was
determined by using 100-fold gradient dilutions of input
plasmid DNA. All typical amplification plots involved
each HPV type for E2 and E6/7 plasmid DNA (change
in the fluorescent signal versus cycle number). HPV-16
E6/7 plasmid DNA amplification plots are in Figure 1a:
the crossing points for the real-time PCR ranged from
10
10 to 1 copy for HPV-16 E6/E7 DNA (dilution factor
100) when present in amounts from 1 ng to 0.1 fg.
Hence, we were able to detect HPV at amounts as low
as 0.1 fg, equivalent to 1 copy. The standard curve
showed a dynamic linear range for quantification across
copy number over the entire range of dilution concen-
trations on bivariate correlation analysis (R
2 = 0.9926)
(Figure 1b). Similar results were obtained with amplifi-
cation plots for E2 and E6/7 genes of HPV-16, -18 and
-58 and the b-globin standard (data not shown).
Because HPV-16 integration often disrupts the E2
gene, recent assays measuring HPV-16 integration were
based on quantification with real-time PCR of HPV-16
E6/7 relative to E2 [16]. As previous study proposed,
assignment of integrated, mixed or episomal physical
status of HPV DNA was calculated for each clinical spe-
cimen and determined by measuring the ratio of E2 to
E6/7 [17]. The protocol for the assay for ratio of E2 to
E6/7 was modified to include dual standard curves of E2
and E6/7. Table 2 shows the standards for determining
the HPV-16, -18 and -58 DNA physical statuses with
ratios of E2 to E6/7. Each ratio of E2 to E6/7 was calcu-
lated from the same respective template. The ratio cut-
off (mean ± SE) of E2 to E6/7 loads for each HPV type
were calculated by E2 and E6/7 gene amplification with
Table 1 PCR primer sequences for human papillomavirus
(HPV) and b-globin
Gene Primer Primer Sequence (5’®3’) Product AT
‡
(°C)
HPV-16 E6/
7
F* GAATGTGTGTACTGCAAGCA 195 bp 56
R
† GTTGTATTGCTGTTCTAAGTTGT
HPV-16 E2 F ACTGTGGTAGAGGGTCA 177 bp 56
R TTCGTTGCTGCTAAA
HPV-18 E6/
7
F GTATGGACCTAAGGCAACA 155 bp 52
R GTCGGGCTGGCAAA
HPV-18 E2 F ACGGTATCCGCTACTCAG 140 bp 52
R GTCTCCGCAAGTCCA
HPV-58 E6/
7
F ATGTGACAGCTCAGACGAGG 166 bp 53
R CAGCTGCTGTAGGGTTCGT
HPV-58 E2 F GTGGGTAGTCGGGTAA 129 bp 53
R TCGTCGTCGCTTTG
b-globin F AACAGCATCAGGAGTGGAC 102 bp 52
R CTGCCTATTGGTCTATTTTCC
*Forward.
†Reverse.
‡Annealing Temperature.
Figure 1 Real-time PCR for human papillomavirus (HPV) DNA
load and physical status assay. (a) Typical amplification plots
obtained by real-time PCR for 7-point series concentration of HPV-
16 E6/7 plasmid DNA. The x axis denotes the cycle number and y
axis the fluorescence intensity over the background. (b) Comparison
of standard curves for the crossing points plotted against the HPV-
16 E2 and E6/7 concentrations. The x axis denotes the cycle
number and y axis the series concentration of HPV-16 plasmid DNA.
Data are mean ± SE (n = 3).
Table 2 Standards to judge HPV physical status by ratio
of E2 to E6/7 gene
Viral E2:E6/7 ratio
Integration Mixed Episomal
HPV-16 <0.001 0.001-0.864 >0.864 (1.005 ± 0.141)
HPV-18 <0.001 0.001-0.823 >0.823 (1.004 ± 0.181)
HPV-58 <0.001 0.001-0.780 >0.780 (0.892 ± 0.112)
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HPV E2 and E6/7 plasmids (range from 10
10 to 1 copy)
representing the episomal-form control and with the
gradient dilution-constructed HPV E6/7 plasmids repre-
senting the integrated-form control. The integration
form was defined by the absence of the E2 signal or
ratio <0.001. Ratios between 0.001 and the lower episo-
mal ratios indicated the mixed form (presence of both
integrated and episomal forms).
Immunohistochemistry
Paraffin-embedded samples from the 54 additional
ESCC cases were used to create a tissue microarray
(TMA) block for IHC detection of HPV-16 expression.
Streptavidin-peroxidase (SP) IHC staining was per-
formed according to the manufacturer’si n s t r u c t i o n sf o r
the SP kit (Maxim.bio Co., China) and was as described
previously [18]. In brief, slides were deparaffinized in
xylene, and endogenous peroxidase was inactivated by
immersing the slides in a 0.3% H2O2-methanol solution
for 30 min at room temperature. Serum blocking solu-
tion (100 μl) was added to each section for 10-min incu-
bation, and then anti-HPV-16 monoclonal antibody
(Maxim.bio Co.) was added for 30 min. After a rinsing,
SP-conjugated polymer (100 μl) was added to each sec-
tion for 10 min. Sections were stained with 100 μlD A B
chromogen (Maxim.bio Co.) and restained with haema-
toxylin for visualization of nuclei for 3 to 10 min. After
a rinsing, slides were counterstained with Mayer’s hema-
toxylin, dehydrated, and mounted. Paraffin sections of
cervical carcinoma served as positive controls. For nega-
tive controls, primary antibodies were substituted with
phosphate buffered saline instead of HPV-16 antibody.
Positive staining for IHC was as described [19] with
modification. Briefly, staining for HPV-16 was mainly in
cytoplasm. The immunoreactivity for all proteins was
defined as follows: strongly positive (++), more than
50% of tumor cells stained; positive (+), more than 25%
of the cells stained; slightly positive (±), more than 10%
of the tumor cells stained; and negative (-), less than
10% of the tumor cells stained or tumor cells lacking
immunoreactivity (Figure 2). All slides were observed by
2 independent pathologists in a double-blinded method,
and the final concordant results were adopted.
Statistical analysis
The presence of HPV DNA among different groups was
analyzed by chi-square test. HPV viral load, physical sta-
tus and HPV-16 expression were analyzed by cancer
type, age, lymph-node metastasis and cancer grade by
independent-samples t test, one-way ANOVA, chi-
square test, Kruskal-Wallis assay, Mann-Whitney-U,
Fisher exact test or Spearman correlation analysis as
appropriate. The level of statistical significance was set
at 0.05 (2-sided). All analyses involved use of SPSS v16.0
(SPSS Inc., Chicago, IL).
Results
Prevalence, viral loads and physical status of HPV-16, -18
and -58
The detection rates for total infection with HPV-16, -18
a n d- 5 8D N Ai nE S C Co rC S C Ct i s s u ew e r es i g n i f i -
cantly higher than those of their corresponding controls:
50.00% vs. 33.33% for ESCC, P = 0.045; and 79.48% vs.
18.52% for CSCC, P < 0.001. Patients with CSCC
showed a higher total detection rate than those with
ESCC (P = 0.005). HPV-16 was the most prevalent type
of single infection in all groups, followed by HPV-58
and -18 (Table 3).
The overall viral loads of HPV-16, -18 and -58 infec-
tion are listed in Table 3. Our data showed no signifi-
cant difference in mean viral loads of HPV-16, -18 and
-58 within each group. However, the combined viral
load for all HR-HPVs in ESCC and CSCC patients was
significantly higher than that of their corresponding
controls: ESCC, 2.55 ± 3.19 vs. 0.55 ± 0.57 copies/cell (P
= 0.029); and CSCC, 361.29 ± 441.75 vs. 30.87 ± 57.39
copies/cell (P < 0.001). In addition, the mean viral load
of HPV-16 in CSCC patients was approximately 141.68-
fold more than that in ESCC patients (468.39 ± 473.36
vs. 2.55 ± 3.19 copies/cells, P = 0.002).
In the present study, we calculated a mean ratio of E2
to E6/7 for each group to determine the degree of viral
Figure 2 Immunohistochemistry results targeting HPV-16 in
tumor samples (cancer grade I-III). The positive expression of
HPV-16, indicated by brown immunohistochemistry signals, located
mainly in the cytoplasm of cancer cells. A, negative (-) in cancer
grade I sample; B, slightly positive (±) in cancer grade II sample; C,
positive (+) in cancer grade II sample; D, strongly positive (++) in
cancer grade III sample. The brown staining was by DAB and the
nuclei were slightly stained by haematoxylin (original magnification
× 200).
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a significantly lower mean ratio of E2 to E6/7 for HPV-
16, -18 and -58 than that of normal controls (0.09 ±
0.14 vs. 0.55 ± 0.40, P < 0.001), which indicates a high
prevalence of the DNA integration form of HPV in
CSCC patients. However, ESCC patients and controls
did not differ in mean ratio of E2 to E6/7 for HPV-16,
-18 and -58 (0.20 ± 0.32 vs. 0.53 ± 0.33, P = 0.06, also
see Table 3). Moreover, for CSCC patients, the mean
ratios of E2 to E6/7 for HPV-16, -18 and -58 were 0.03
± 0.08, 0.06 ± 0.10 and 0.12 ± 0.18, respectively, with no
significant difference in HPV ratios (P = 0.229); similar
results were found for ESCC patients and controls and
CSCC controls.
Furthermore, results for HR-HPV physical status
showed DNA episomal, integrated and mixed forms
(Table 2). HPV DNA integration and mixed forms were
more frequently observed in CSCC patients (100% [31/
31]) than in controls (40.00% [4/10]) (P < 0.001). The
frequency of HR-HPV integration markably increased
with CSCC grade (rs = 0.575, P < 0.001). Similarly, for
ESCC patients, the frequency of HR-HPV integration
was higher than that for ESCC controls (rs =0 . 4 0 5 ,P=
0.002). Overall, the mixed and integrated forms of HPV
were commonly observed in ESCC patients and controls
(91.43% [32/35] vs. 85.00% [17/20]).
Relationship between HPV DNA infection and clinical
characteristics of patients with ESCC or CSCC
We analyzed whether the clinical and histological char-
acteristics of patients with ESCC and CSCC were asso-
ciated with HPV infection. For CSCC patients, HR-HPV
loads were significantly increased and ratios of E2 to
E6/7 were decreased with increased tumour grade of
CSCC (P = 0.008 and P = 0.042, respectively) (Table 4).
For ESCC patients, the integration level was associated
with pathological grade of ESCC (P = 0.015). However,
no significant associations were found between HPV
physical status and patient age or lymph-node metastasis
for CSCC patients. HPV viral loads were not associated
with ESCC patient age, lymph-node metastasis or cancer
grade (Table 4).
Relationship between HPV-16 expression and clinical
characteristics of patients with ESCC
To determine whether the expression of HPV-16 might
have an influence on esophageal malignant progression,
we analyzed HPV-16 expression by clinical characteristics
Table 3 HPV-16, -18 and -58 prevalence, viral load and physical status in patients with ESCC and CSCC, and in their
corresponding controls
Origin Total No. (%) Viral load (copies/cell) Physical status (E2:E6/7 ratio)
Min-max Mean ± SD Mean ± SD Episomal Mixed Integration
HPV16 >0.86 0. 10-0.86 0.001-0.10 <0.001
ESCC 70 21(30.00) 0.02-9.28 2.19 ± 2.60 0.25 ± 0.37 2 5 8 6
NE 60 13(21.67) 0.04-2.08 0.55 ± 0.16 0.51 ± 0.36 3 7 2 1
CSCC 39 19(48.72) 32.03-1546.38 468.39 ± 473.36 0.03 ± 0.08 0 5 5 9
NC 54 8(14.81) 0.12-122.92 26.21 ± 34.26 0.59 ± 0.44 4 3 1 0
HPV18 >0.82 0. 10-0.82 0.00-0.10 <0.001
ESCC 70 8(11.43) 0.00-11.29 2.03 ± 3.88 0.17 ± 0.14 0 1 6 1
NE 60 3(2.00) 0.03-2.25 0.73 ± 1.26 0.37 ± 0.14 0 2 0 1
CSCC 39 7(17.95) 5.14-295.38 174.77 ± 121.20 0.06 ± 0.10 0 2 3 2
NC 54 2(3.70) 1.22-130.51 65.87 ± 91.42 0.60 ± 0.34 1 1 0 0
HPV58 >0.78 0. 10-0.78 0.001-0.10 <0.001
ESCC 70 9(21.43) 0.03-12.56 3.86 ± 3.82 0.17 ± 0.32 1 1 3 4
NE 60 4(6.67) 0.17-2.65 1.68 ± 1.09 0.35 ± 0.31 0 3 1 0
CSCC 39 9(23.08) 4.11-1521.70 280.27 ± 499.13 0.12 ± 0.18 0 3 0 6
NC 54 2(3.70) 0.99-106.59 53.79 ± 74.67 0.64 ± 0.26 1 1 0 0
3 HR-HPVs
ESCC 70 35(50.00) 0.00-12.56 2.55 ± 3.19
a 0.20 ± 0.32 3 6 16 10
d
NE 60 20(33.33) 0.04-2.08 0.55 ± 0.57 0.53 ± 0.33 3 12 3 2
CSCC 39 31(79.48) 4.11-1546.38 361.29 ± 441.75
bc 0.09 ± 0.14 0 9 6 16
ef
NC 54 10(18.52) 0.12-853.43 30.87 ± 57.39 0.55 ± 0.40 6 3 1 0
aZ = -2.594, P = 0.029, compared with NE group;
b Z = -3.115, P = 0.002 and
cZ = -4.827, P < 0.001, compared with ESCC patients and NC group, respectively,
and calculated with the Mann-Whitney-U test.
d c
2 = 12.703, P = 0.004;
e c
2 = 22.544, P < 0.001;
f c
2 = 8.850, P = 0.022 compared with NE group. NC group and ESCC patients, respectively, and calculated with
the Chi-square test or Fisher exact test as appropriate.
ESCC, esophageal squamous cell carcinoma; CSCC, cervical squamous cell carcinoma; NE, normal esophagus; NC, normal cervix.
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expression was detected in 59.26% of ESCC tissues and
was positively, although weakly, correlated with patholo-
gical grade of cancer and age of ESCC patients (rs =
0.301, P = 0.027; rs = 0.229, P = 0.028, respectively). No
relationship was found with lymph-node metastasis.
Discussion
We adopted a comprehensive methodology to assess the
prevalence, viral load and physical status of infection
with HR-HPV-16, -18 and -58, the 3 most common
HR-HPVs, in patients with ESCC and CSCC and the
expression of HPV-16 in patients with ESCC. We aimed
to explore the characteristics of HR-HPV DNA in the
carcinogenesis of ESCC compared with CSCC.
Infection with the 3 types of HR-HPV associated
with CSCC (79.48%) in the Shantou region was con-
sistent with that in other regions in China, but the
infection in controls was higher (18.52% vs. 6.87%)
[8,20]. This increased rate should be interpreted with
caution because of the small number of cases in our
s t u d y .F o rE S C Cp a t i e n t s ,t h e total infection rate for
all 3 viruses was greater than that of their controls.
Among the HR-HPV types, HPV-16 was the most pre-
dominant in all esophageal tissues. Our results for
HPV-16 and -18 infection rates in Shantou were simi-
lar to those from a previous study (52.4%) [21] and
were higher than those in other regions [22,23]. Inter-
estingly, this distribution of HR-HPV in esophageal
lesions was in agreement with observations for
cervical lesions [24].
Table 4 Relation of viral load and ratio of E2 to E6/7 of HP-HPV infection and clinical characteristics of ESCC and CSCC
patients
Characteristics No. of subjects HPV viral load
(mean ± SE)
t/F/Z statistic P* HPV E2:E6/7 ratio
(mean ± SE)
t/F/Z /statistic P*
ESCC patients
Age (years)
54.42 ± 7.86 38 2.55 ± 3.19 -0.152 0.364
# 0.201 ± 0.325 0.049 0.771
#
Lymph node metastasis
Yes 20 2.98 ± 3.81 0.879 0.385 0.22 ± 0.30 -0.731 0.478
No 18 2.07 ± 2.34 0.18 ± 0.34
Cancer grade
I 13 1.65 ± 3.42 0.39 ± 0.43
II 20 2.96 ± 3.32 0.799 0.458 0.12 ± 0.23 8.361 0.015
III 5 3.24 ± 1.60 0.05 ± 0.11
CSCC patients
Age (years)
43.42 ± 8.44 35 361.29 ± 441.74 -0.108 0.537
# 0.09 ± 0.14 -0.184 0.289
#
Lymph node metastasis
Yes 10 330.03 ± 316.40 -0.110 0.913 0.11 ± 0.12 -1.278 0.201
No 25 373.80 ± 448.21 0.08 ± 0.16
Cancer grade
I 14 188.68 ± 374.64 0.17 ± 0.19
II 12 340.28 ± 262.40 9.542 0.008 0.06 ± 0.09 6.363 0.042
III 9 660.97 ± 592.94 0.007 ± 0.001
*P values for the differences of HPV viral load and ratio of E2 to E6/7 among different groups was calculated with the independent-samples t test or Mann-
Whitney-U test, one-way ANOVA or Kruskal-Wallis assay as appropriate.
# P values for the correlation between the age of patients and HPV viral load, as well as HPV ratios of E2 to E6/7 were calculated by Spearman correlation.
ESCC, esophageal squamous cell carcinoma; CSCC, cervical squamous cell carcinoma.
Table 5 Correlation between HPV-16 expression and
clinical characteristics of ESCC patients
Characteristics No. HPV-16 * rP
#
-±+ + +
Age (years)
53.13 ± 10.05 54 22 12 15 5 0.299 0.028
Lymph-node metastasis
Yes 36 16 8 9 3 0.115 0.408
No 18 6 4 6 2
Cancer grade
I 16 8 3 2 1 0.301 0.027
II 28 13 8 8 3
III 10 1 1 5 1
* indicates positive on immunohistochemistry staining.
# P values for the correlation between HPV-16 expression and clinical
characteristics of ESCC patients were calculated by Spearman correlation or
Fisher exact test as appropriate.
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have varied in ESCC patients from geographically differ-
ent areas [5], but are consistently high in CSCC patients
[25]. This significant difference may result from HPV
DNA copy numbers in host tissues. Evidence from our
study revealed that the average viral load for HR-HPV
for CSCC patients was significantly higher than that for
ESCC patients in Shantou region; the mean viral load
for HPV-16 was 2.55 ± 3.19 copies/cell in ESCC tissues.
This low figure was also found in a Chinese study of EC
tissues (<1 to 157 copies/cell) [13,26] and a Finnish
study of head and neck SCCs (4.6 to 49 copies/cell)
[27]. Extremely low levels of HPV DNA load (even 0.01
copies/cells) in ESCC tissues may exceed the detection
ability of some techniques such as regular PCR and con-
ventional in situ hybridization (ISH), which limits detec-
tion to <10-50 copies/cell [28]. Our positive results for
<10 copies of HPV DNA would be out of the detection
range with use of general PCR and ISH technology. This
low detection rate might explain why we failed to mea-
sure the level of HPV mRNA in our paraffin-embedded
tissue by RT-PCR and the low detection rates we found
with regular PCR in our previous study. This low HPV
infection load was not correlated with clinical character-
istics such as age, cancer grade or lymph-node metasta-
sis of ESCC patients and their controls. However,
increased levels of all HR-HPVs with increasing cancer-
ous grade indicated a dose-dependent association of
viral load and cancer grade.
Epidemiologic and molecular studies have shown that
HR-HPV DNA integration is considered a prerequisite
for the development of several malignant lesions [29,30].
For the integration level of viral DNA, we found no dif-
ferences between CSCC and ESCC lesions for the level
of integration of HPV-16, -18 and -58; most infected
CSCC or ESCC control subjects carried the episomal
form of the virus, whereas the mixed and integrated
forms were predominant in ESCC and invasive cervical
carcinomas. For ESCC patients, specifically, we found
both ratios of HPV DNA integration and expression of
HPV-16 protein increased with ESCC grade. The inte-
gration occurs in the early stage of esophageal carcino-
genesis and was associated with the severity of the
cancer. So the increased expression of the E6 and E7
oncoproteins in ESCC might re s u l tf r o md i s r u p t i n gt h e
E2 open reading frame when HPV integrates into the
host genome [31-33]. Although the direct evidence of
HPV-16 transcription and expression derived from inte-
grated HPV DNA is still unclear, from previous studies,
HPV E6- and E7-encoding cDNAs derived from inte-
grated viral oncogene transcripts have a much stronger
transforming capacity in primary cells than cDNAs
derived from episome-derived transcripts [11]. The rela-
tive expression levels of the viral oncogenes and their
corresponding gene products appear to be directly influ-
enced by the sequence context of individual integration
sites in cervix, head, neck, penile and tonsil carcinogen-
esis [34,35]. So the potential connections among HPV
DNA integration, transcription and expression, as well
as its clinical value, need to be confirmed with more
studies.
Our data confirmed for CSCC that the high preva-
lence, viral loads and integration rates of HR-HPV were
the most important risk factors for cervical carcinogen-
esis. We also found relatively low HPV-16, -18 and -58
viral load in ESCC patients, which is consistent with the
relatively low HR-HPV DNA viral load found in some
cervical carcinoma cell lines such as SiHa cells (1-2
copies/cell for HPV-16) and HeLa cells (10-50 copies/
cell for HPV-18). However, the low viral load, particu-
larly with a common integrated viral genome and high
expression of its onco-protein, may be sufficient to lead
to or promote carcinogenesis, especially because of the
high incidence of EC.
Our study contains some limitations. The selection
bias cannot be avoided because of the relatively small
number of samples collected, which may reduce the
representativeness of our results and capacity for infer-
ence. Heterogeneity between ESCC and CSCC patient
ages also existed because of the small number of sam-
ples in these groups.
Conclusions
Our data show that a relatively low HPV copy number
and infection rate in ESCC is unlikely to play an essen-
tial a role in the carcinogenesis of ESCC as in cervical
cancer. However, the presentation of the physical status
and expression of the HR-HPV types in ESCC strongly
suggests a possible role of oncogenic HPV infection in
carcinogenesis of ESCC, at least for patients in the
Shantou region of China. Because esophageal carcino-
genesis is a complex, multi-step process, additional work
is warranted to elucidate the underlying molecular
mechanisms and the genetic changes associated with
HPV infection in the development of esophageal cancer.
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